CVS stock faces headwind as Star ratings drop, TD Cowen says
CVS Health (NYSE:CVS) is expected to see a decline in Medicare Advantage enrollment in 4-star rated plans for 2027, according to TD Cowen. This could result in a $720 million impact and a $0.41 headwind to adjusted EPS in 2028. Analysts have mixed views, with some maintaining positive ratings and price targets. CVS trades at $87.80 with a market cap of $112 billion.
How this was made
The 30-second read
Why it matters
The projected earnings headwind may influence investor sentiment ahead of the upcoming earnings release.
Market read
First disclosure of a material earnings drag for CVS, relevant for short‑term positioning before earnings.
What to watch
Analyst upgrades and strong 340B pricing exposure could cushion the impact.
Background
TD Cowen analysis of CMS star rating data for CVS Health, highlighting a decline in 4‑star and 4.5‑star Medicare Advantage enrollment for 2027.
Ticker impact
TD Cowen projects a $0.41 EPS headwind for 2028 due to lower Medicare Advantage star ratings, a new estimate not previously disclosed.
likely downward pressure as investors price in the $0.41 EPS hit and $720M impact.
Quantified earnings impact and timing before upcoming Q3 earnings make the news actionable.
Market effects
Potential drag on healthcare sector peers as Medicare Advantage rating concerns may affect valuation multiples.
U.S. healthcare stocks could see modest weakness in the short term.
Limited to U.S. markets; no direct global effect.
Counterpoint
If CVS can offset the rating hit through benefit design, the stock may be undervalued at current levels.
Key entities
- companyCVS Health
U.S. healthcare retailer and pharmacy benefit manager.
- analystTD Cowen
Research firm providing the star rating impact estimate.
